Better Coronavirus Stock: Quidel or Guardant Health?
Throughout the turmoil of the pandemic, Quidel Corporation (NASDAQ: QDEL) and Guardant Health (NASDAQ: GH) are continuing to innovate with their medical testing and diagnostic products. Both companies are experiencing rapid revenue growth, and neither is being held back by cumbersome levels of debt or regulatory obstacles to getting their products approved for sale. What's more, the two stocks have grown furiously this year, and each company has a concrete vision for where and how to compete in the near future.
Still, the companies are at significantly different phases in their life cycles. Guardant has yet to reach profitability, whereas Quidel has been profitable for quite some time. Similarly, Quidel has a large collection of different diagnostic tests, whereas Guardant has one primary product and a couple of others in the works.
These companies have taken different approaches to developing products for the coronavirus market. Let's examine each stock to see which is the better buy based on their competitive positioning in and outside of the coronavirus space.
Source Fool.com
